Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2017-12-15
2024-01-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Congestive Heart failure is a frequent pathology and its prevalence increases with age. Its prognosis stays pejorative despite years of major therapeutical progress. In recent trials, all-cause mortality rates at 1-year reach up to 20% and 50% at 5 years.
Medical care of congestive heart failure is based on precise international recommendations. The association of Beta-Blockers, renin-angiotensin system blockers, mineralocorticoid receptor antagonists, represent the basis of the pharmacological treatment.
Cardiac resynchronization treatment and implantable cardioverter-defibrillator are additional efficient treatments that reduce events in appropriately selected patients.
Despite these improvements, the prognostic of congestive heart failure in registers is worse than those observed in randomized trials. This can be explained by differences in congestive heart failure patient populations and/or by a less rigorous medical care where treatments are not optimized.
The evaluation of medical care in congestive heart failure is today of utmost importance.
Integrating new pharmacological molecules, medical devices and the application of new recommendations have major interest for documentation and practical changes.
The main objective of this cohort will be to evaluate the evolution of the 12-month quality of life score of a HF patient and the characteristics and treatments associated with it.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation
NCT05097898
Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation
NCT04343430
Chronic Heart Failure - COngestion eValuation
NCT05089149
Acute Heart Failure With Reduced Ejection Fraction - COngestion Discharge Evaluation
NCT04343443
Consultation at 8 Days to Reduce Hospitalisations in Heart Failure Patient
NCT01834833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Congestive Heart Failure patients Cohort
Cluster of patients with congestive heart failure NYHA ≥2, with at least one cardiac decompensation, NT-proBNP (N-terminal pro-brain natriuretic peptide) \> 500 ng/l. Will be followed during 18 months.
Blood sampling and Quality of life questionnaire.
Blood sampling and Quality of life questionnaire.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling and Quality of life questionnaire.
Blood sampling and Quality of life questionnaire.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalization for cardiac decompensation
* A medical follow-up for stable congestive heart failure with at least one cardiac decompensation event
* NT-proBNP \> 500 ng/l in the month before Baseline (or BNP \> 150 ng/l)
* NYHA ≥ 2
* Aged over 18
* Signature of the informed consent
Exclusion Criteria
* Patients on long term assistance or with heart transplant
* Impossibility to give patients clear information
* Loss of autonomy, dementia, major dependence
* Patients without health coverage
* Patient with no legal protection
* Pregnant woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospices Civils de Lyon - Hôpital Louis Pradel, Centre d'Investigation Clinique
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL17_0250
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.